Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;31(2):166-178.
doi: 10.1007/s12282-023-01531-9. Epub 2023 Dec 26.

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition

Masaaki Kawai  1 , Shoichiro Ohtani  2 , Motoki Iwasaki  3 , Seiichiro Yamamoto  4 , Kiyoshi Takamatsu  5 , Hitoshi Okamura  6 , Masami Arai  7 , Tsunehisa Nomura  8 , Shinji Ozaki  9 , Ken-Ichi Shibata  10 , Ayaka Akabane  10 , Fuyuhiko Motoi  10 , Chikako Yamauchi  11 , Yutaka Yamamoto  12 , Hiroji Iwata  13 , Shigehira Saji  14
Affiliations

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition

Masaaki Kawai et al. Breast Cancer. 2024 Mar.

Abstract

The Japanese Breast Cancer Society Clinical Practice Guidelines for Epidemiology and Prevention of Breast Cancer, 2022 Edition.

Keywords: 2022; Breast; Epidemiology; Guideline; JBCS; Prevention.

PubMed Disclaimer

Conflict of interest statement

MK received honoraria for lectures from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, Kyowa-Kirin, MSD, Novartis, and Pfizer; SO received honoraria for lectures from AstraZeneca, Chugai, Eizai and Eli Lilly; KT received honoraria for lectures from ASKA Pharmaceutical Co. Ltd., Bayer Yakuhin, Ltd., Fuji Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Tsumura & Co; YY received research funding from Chugai, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Lilly, Nippon-Kayaku, Novartis, Pfizer, Taiho and Takeda; YY received honoraria for lectures from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Exact Science, Kyowa-Kirin, Lilly, MSD, Nippon-Kayaku, Novartis, Pfizer, Sysmex, Taiho and Takeda; YY participated on advisory boards for AstraZeneca, Chugai, Daiichi-Sankyo, Lilly, MSD, Novartis and Pfizer; YY was a member of the board of directors of the Japanese Breast Cancer Society and Japan Breast Cancer Research Group; HI received grants from AstraZeneca, Chugai and Daiichi-Sankyo; HI received consulting fees from AstraZeneca, Chugai, Daiichi-Sankyo, Gilead, Lilly, MSD and Pfizer; HI received honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Kyowa Kirin, Lilly, MSD, Pfizer and Taiho; SS received grants from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, MSD and Taiho and Takeda; SS received honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin, MSD, Nipponkayaku, Novartis, Ono, Pfizer, Taiho and Takeda; SS participated on advisory boards for AstraZeneca, Chugai/Roche, Daiichi-Sankyo, Eli Lilly, Kyowa Kirin, MSD and Pfizer; SS was a member of the board of directors of Breast International Group (BIG), Japan Breast Cancer Research Group (JBCRG), Japanese Breast Cancer Society (JBCS) and Japanese Society of Medical Oncology (JSMO); MI, SY, HO, MA, TN, SO, KS, AA, FM, CY have no conflict of interest.

Figures

Fig. 1
Fig. 1
Annual trends in breast cancer morbidity and mortality among Japanese women by age standardization on the world population (per 100,000 population). From: Updated trends in cancer in Japan: incidence in 1985–2015 and mortality in 1958–2018 a sign of decrease in cancer incidence. J Epidemiol. 2021; 31: 426–450 [8]. Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) (1958–2019)
Fig. 2
Fig. 2
Annual trends in breast cancer mortality among Japanese women by age group (per 100,000 population). From: Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) (1958–2019)
Fig. 3
Fig. 3
Breast cancer mortality among Japanese women by age group (per 100,000 population). From: Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) (Year 1958–2019)
Fig. 4
Fig. 4
Yearly change in breast cancer morbidity among Japanese women by age group (per 100,000 population). From: Updated trends in cancer in Japan: incidence in 1985–2015 and mortality in 1958–2018—a sign of decrease in cancer incidence. J Epidemiol. 2021; 31: 426–450 [8]
Fig. 5
Fig. 5
Breast cancer incidence among Japanese women by age group (per 100,000 population). From: Updated trends in cancer in Japan: incidence in 1985–2015 and mortality in 1958–2018 a sign of decrease in cancer incidence. J Epidemiol. 2021; 31: 426–450 [8]
See this image and copyright information in PMC

References

    1. Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, et al. The Japanese Breast Cancer Society clinical practice guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer. 2020;27:1–3. doi: 10.1007/s12282-019-01021-x. - DOI - PMC - PubMed
    1. Minds (Medical Information Distribution Service) Manual for Clinical Practice Guideline Development 2020 ver. 3.0. 2020.
    1. The Japanese Breast Cancer Society clinical practice guideline for treatment of breast cancer, 2022 edition. The Japanese Breast Cancer Society Clinical Practice Guideline. Kanehara & Co., Ltd: Tokyo; 2022.
    1. The Japanese Breast Cancer Society clinical practice guideline for epidemiology and diagnosis of breast cancer, 2022 edition. The Japanese Breast Cancer Society Clinical Practice Guideline. Kanehara & Co., Ltd: Tokyo; 2022.
    1. Taira N, Arai M, Ikeda M, Iwasaki M, Okamura H, Takamatsu K, et al. The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. Breast Cancer. 2015;22:16–27. doi: 10.1007/s12282-014-0555-x. - DOI - PubMed